Product
Pegvisomant
3 clinical trials
4 indications
Indication
AcromegalyIndication
Insulin Receptor MutationIndication
Partial LipodystrophyIndication
FibrosisClinical trial
Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in Acromegalic Patients Failing to Respond to Lanreotide Autogel 120 mg AloneStatus: Completed, Estimated PCD: 2008-10-01
Clinical trial
Phase II Study of Growth Hormone Inhibition Using Pegvisomant In Severe Insulin ResistanceStatus: Recruiting, Estimated PCD: 2025-01-30
Clinical trial
Growth Hormone as a Model for Reversible Activation of Adipose Tissue FibrosisStatus: Active (not recruiting), Estimated PCD: 2023-12-31